Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (61-70 of 263) with videos related to

Pageof 27
Sort By:
Cancer|May 26, 2004
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phaseJorge Cortes, Susan O'Brien, Alfonso Quintas, et al.
Blood|February 1, 2008
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cellsJi Wu, Feng Meng, Henry Lu, et al.
Biochemical Pharmacology|May 31, 2011
Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activityVaibhav Kapuria, Luke F Peterson, H D Hollis Showalter, et al.
Leukemia Research|June 14, 2025
A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosisMoshe Talpaz, Aaron T Gerds, Roger Lyons, et al.
Blood|September 23, 2006
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureAlfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, et al.
Clinical Case Reports|July 11, 2018
Primary myelofibrosis evolving to an aplastic appearing marrowJordan K Schaefer, Sarah M Choi, Gary D Luker, et al.
Leukemia|April 15, 2026
Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX modelsMalathi Kandarpa, Luke F Peterson, Harish Potu, et al.
Journal of Translational Medicine|September 12, 2015
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosisCatriona Jamieson, Robert Hasserjian, Jason Gotlib, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2021
Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 10<sup>9</sup>/L): Final Analysis of an Open-Label Phase 2 StudyMoshe Talpaz, Josef Prchal, Lawrence Afrin, et al.
Mayo Clinic Proceedings|March 11, 2005
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatmentAyalew Tefferi, Gordon W Dewald, Mark L Litzow, et al.
Pageof 27

Showing results (61-70 of 263) with videos related to

Sort By:
Pageof 27
Cancer|May 26, 2004
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phaseJorge Cortes, Susan O'Brien, Alfonso Quintas, et al.
Blood|February 1, 2008
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cellsJi Wu, Feng Meng, Henry Lu, et al.
Biochemical Pharmacology|May 31, 2011
Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activityVaibhav Kapuria, Luke F Peterson, H D Hollis Showalter, et al.
Leukemia Research|June 14, 2025
A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosisMoshe Talpaz, Aaron T Gerds, Roger Lyons, et al.
Blood|September 23, 2006
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureAlfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, et al.
Clinical Case Reports|July 11, 2018
Primary myelofibrosis evolving to an aplastic appearing marrowJordan K Schaefer, Sarah M Choi, Gary D Luker, et al.
Leukemia|April 15, 2026
Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX modelsMalathi Kandarpa, Luke F Peterson, Harish Potu, et al.
Journal of Translational Medicine|September 12, 2015
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosisCatriona Jamieson, Robert Hasserjian, Jason Gotlib, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2021
Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 10<sup>9</sup>/L): Final Analysis of an Open-Label Phase 2 StudyMoshe Talpaz, Josef Prchal, Lawrence Afrin, et al.
Mayo Clinic Proceedings|March 11, 2005
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatmentAyalew Tefferi, Gordon W Dewald, Mark L Litzow, et al.
Pageof 27